OA12.02 | Comparison of co-immunization of DNA and protein in the same anatomical sites and in contralateral sites to identify mechanisms of protective immune response | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA12.03 | Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T cell immunogenicity and breadth | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA12.04LB | A VSV-based HIV-1 vaccine provides protection in macaques against low dose cross-clade SHIVenv_SF162_P3 challenge | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA12.05 | Improved in vitro expression and in vivo immunogenicity of a candidate MVA-vectored HIV-1 vaccine compared to SAAVI MVA-C | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA15.01 | Heterologous vaccination with DNA and two different poxvirus vectors, expressing HIV-1 envelope on the surface of Gag virus-like particles, elicit autologous Tier 2 neutralising antibodies | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA15.02 | In vitro and in vivo analyses of HIV-1 clade C Envelope trimers highlight optimal antigenic profiles of novel HIV-1 Env-based vaccine candidates | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA15.03 | Novel trimer-only (TO) producing HIV-1 envelope glycoprotein constructs for inducing broadly neutralizing antibody responses by genetic vaccination | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA15.04 | Structural basis of neutralizing antibodies targeting the CD4-binding site and fusion peptide elicited by immunization with heterologous HIV-1 Env in NHP | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA15.05LB | Cross-reactivity between HIV-1 bnAbs and parasite glycans | Oral Abstract Session | Novel vaccine and other prevention approaches |
OA18.05LB | Multivalent antigen presentation increases the antibody binding breadth and neutralizing potency upon the immunization with a self-assembling HIV env vaccine | Oral Abstract Session | Novel vaccine and other prevention approaches |